(BPT) - Clinical depression or major depressive disorder (MDD) is one of the most common mental health disorders, with almost 21 million adults in the United States having experienced at least one major depressive episode in 2020.¹ Even though it is one of the leading causes of disability in the US, an estimated one-third of US adults living with MDD do not respond adequately to two different antidepressants during the same depressive episode, often defined as treatment-resistant depression (TRD).²

For these patients, there are treatments available that are backed by safety and efficacy data, like SPRAVATO^® (esketamine) CIII nasal spray, which received FDA approval to treat adults with TRD and to treat depressive symptoms in adults with MDD with acute suicidal thoughts or actions, in combination with an oral antidepressant.³

Patient safety is a top priority for Johnson & Johnson. This is why Johnson & Johnson collaborated with the U.S. FDA to establish a Risk Evaluation and Mitigation Strategy (REMS) program for SPRAVATO^®, implementing stringent safety and post-administration protocols.³

SPRAVATO^® is derived from ketamine³; however, it's important to note that it is distinctly different from ketamine. Learn more about the proven safety and efficacy of SPRAVATO^® and how it is different than ketamine in the infographic below.

References:

1. National Institute of Mental Health. Major depression. Accessed July 15, 2024. https://www.nimh.nih.gov/health/statistics/major-depression
2. Agency for Healthcare Research and Quality. Definition of treatment-resistant depression in the Medicare population. Accessed July 15, 2024. https://www.ncbi.nlm.nih.gov/books/NBK526366/pdf/Bookshelf_NBK526366.pdf
3. SPRAVATO^® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.

cp-466323v1